Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are:
1.1 To determine the efficacy of liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) administered by
aerosolization to patients with metastatic endometrial cancer.
1.2 To determine toxicity profile of L9NC administered by aerosolization for 5 consecutive
days per week X 8 weeks, every 10 weeks.
1.3 To perform a pharmacology study of L9NC in the plasma and the lungs after aerosolization.
A specific protocol will be written for this part.